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M A J O R A R T I C L E
A Randomized Trial of a Standard Dose of
Edmonston-Zagreb Measles Vaccine Given at
4.5 Months of Age: Effect on Total Hospital
Admissions
Cesario L. Martins,1 Christine S. Benn,2 Andreas Andersen,1 Carlito Balé,1 Frederik Schaltz-Buchholzer,1 Vu An Do,1
Amabelia Rodrigues,1 Peter Aaby,1 Henrik Ravn,2 Hilton Whittle,3 and May-Lill Garly1
1Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau; 2Research Center for Vitamins and Vaccines, Bandim Health Project, Statens Serum
Institut, Copenhagen, Denmark; and 3London School of Hygiene and Tropical Medicine, United Kingdom
Observational studies and trials from low-income countries indicate that measles vaccine has beneﬁcial nonspe-
ciﬁc effects, protecting against non–measles-related mortality. It is not known whether measles vaccine protects
against hospital admissions. Between 2003 and 2007, 6417 children who had received the third dose of diphthe-
ria, tetanus, and pertussis vaccine were randomly assigned to receive measles vaccine at 4.5 months or no
measles vaccine; all children were offered measles vaccine at 9 months of age. Using hospital admission data
from the national pediatric ward in Bissau, Guinea-Bissau, we compared admission rates between enrollment
and the 9-month vaccination in Cox models, providing admission hazard rate ratios (HRRs) for measles
vaccine versus no measles vaccine. All analyses were conducted stratiﬁed by sex and reception of neonatal
vitamin A supplementation (NVAS). Before enrollment the 2 groups had similar admission rates. Following en-
rollment, the measles vaccine group had an admission HRR of 0.70 (95% conﬁdence interval [CI], .52–.95),
with a ratio of 0.53 (95% CI, .32–.86) for girls and 0.86 (95% CI, .58–1.26) for boys. For children who had not
received NVAS, the admission HRR was 0.53 (95% CI, .34–.84), with an effect of 0.30 (95% CI, .13–.70) for
girls and 0.73 (95% CI, .42–1.28) for boys (P = .08, interaction test). The reduction in admissions was separately
signiﬁcant for measles infection (admission HRR, 0 [95% CI, 0–.24]) and respiratory infections (admission
HRR, 0.37 [95% CI, .16–.89]). Early measles vaccine may have major beneﬁts for infant morbidity patterns and
healthcare costs.
Clinical trials registration. NCT00168558.
Keywords. Edmonston-Zagreb; hospital admissions; measles infection; measles vaccination; morbidity reduc-
tion; nonspeciﬁc effects of vaccine.
The current policy to vaccinate against measles at 9
months of age in low-income countries was formulated
in the mid-1970s on the basis of studies of seroconversion
at different ages; the overall effect of measles vaccine
on morbidity and mortality was not examined. When
measles vaccine was introduced at demographic surveil-
lance sites in Africa in the late 1970s and early 1980s,
several studies reported reductions in child mortality of
≥40% [1–7]. Studies in Bangladesh and Haiti provided
similar results [8–10]. This effect was larger than expected
since measles infection causes only 10% of all childhood
deaths [11]. Subsequent randomized trials have con-
ﬁrmed that measles vaccine has beneﬁcial nonspeciﬁc
effects, and therefore measles vaccine probably reduces
severity or provide protection against infections other
than measles [12].
Little is known about the underlying mechanisms
behind these nonspeciﬁc effects of measles vaccine; in
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particular, there is no information on how measles vaccine
affects morbidity patterns. During 2004–2007, we conducted a
trial of early measles vaccination, randomly assigning children
to receive measles vaccine early, at 4.5 months of age, in addi-
tion to the recommended measles vaccine at 9 months of age or
to receive no vaccine at 4.5 months of age and only the recom-
mended measles vaccine at 9 months of age. As hypothesized,
early receipt of measles vaccine reduced mortality between 4.5
and 36 months of age by 36% (95% conﬁdence interval [CI],
2%–58%) for girls, but the effect was limited for boys (reduc-
tion, 5% [95% CI, −36% to 36%]) [13]. The trial also revealed
that receipt of neonatal vitamin A supplementation (NVAS)
removed the beneﬁcial effect of early receipt of measles vaccine
[13].
To understand possible biological mechanisms and the
health implications of these ﬁndings, it will be important to de-
termine which morbidity patterns are affected by the nonspe-
ciﬁc effects. We therefore used data from the national pediatric
ward in Bissau, Guinea-Bissau, to examine whether measles
vaccine affected the rate of hospital admission and whether
effects differed for different types of infection. We compared
the admission rate from enrollment and until the 9-month
measles vaccination for children randomly assigned to receive
measles vaccine or no measles vaccine at 4.5 months of age, the
latter children having the third dose of diphtheria, tetanus, and
pertussis vaccine (DTP3) as their most recent vaccination.
METHODS
Setting and Study Population
The trial was conducted in Guinea-Bissau in the Bandim
Health Project (BHP) study area, which covers 6 districts
with approximately 102 000 inhabitants [14]. All houses are
visited every month to register new pregnancies and births.
All children are visited every 3 months until 3 years of age
to collect information on breast-feeding status, infections, hos-
pital admissions, and vaccination status. Coverage for DTP3
and measles vaccine was 89% and 88%, respectively, in the
12–23-month age group when the trial started [15].
Objectives and Study Design
The trial has been described in detail elsewhere [13, 16]. Brieﬂy,
the primary objective was to measure the effect of different
measles vaccine schedules on overall mortality between 4.5 and
36 months of age. The children had to have received DTP3 at
least 4 weeks before enrollment. The trial included 3 arms: stan-
dard-dose Edmonston-Zagreb (EZ) measles vaccine (Serum In-
stitute of India [Pune, India]) at 4.5 and 9 months of age
(group A), no vaccine at 4.5 months of age and standard-dose
EZ measles vaccine at 9 months of age (group B), and no
vaccine at 4.5 months of age and standard-dose Schwarz
measles vaccine (Rouvax [Aventis, France]) at 9 months of age
(group C). All children were invited back at 9 months of age to
receive measles vaccine. EZ measles vaccine provides better se-
roconversion in the presence of maternal antibody and may
boost better than Schwarz measles vaccine [17] and was there-
fore selected for the early measles vaccine arm.
The sample size was based on detecting a 25% difference in
mortality between the early receipt group (group A) and the
control groups (groups B and C). We hypothesized a priori that
beneﬁcial effects on child survival would be strongest for girls
and in the dry season (December–May) [13]. The trial was
funded to examine antibody responses, clinical protection, and
survival. However, we maintained a registration of hospital ad-
missions during the trial and therefore examined how measles
vaccine affected admission patterns.
Enrollment, Informed Consent, and Randomization
Eligible infants were identiﬁed in the registration system. The
mothers or guardians were invited to the local health center
and received an oral and a written explanation of the study
from a physician. The physician performed a medical examina-
tion. If agreeing to participate, the mothers selected an enve-
lope with the allocation number.
Information on Hospital Admissions
Three health centers provide primary care in the study area.
Severe cases are sent to the national hospital. The BHP has
maintained a register for admissions to the pediatric ward since
the 1990s. This is the only specialized pediatric ward in the
country and is used as general pediatric ward for residents in
Bissau. Staff from BHP register all admitted children by name,
sex, date of birth, name of mother, residential area, and
outcome. Using the ID-number on the vaccination card, the as-
sistant assigns the BHP identiﬁcation number. For children
who do not bring a card and cannot be identiﬁed easily, a
senior data manager identiﬁes the children, using all available
information. For the present analysis, it was veriﬁed that
correct identiﬁcation numbers had been assigned.
The responsible physician assigns primary and secondary
diagnoses. We have used the primary diagnosis with the excep-
tion that 4 children who had “measles” as a secondary diagnosis
were reclassiﬁed as having “measles” as the primary diagnosis.
Malaria was to be diagnosed by microscopy of thick and thin
blood slides, but a diagnosis of malaria was often made by clini-
cians even though parasites had not been detected [18].
At the 9-month vaccination, the mother was asked whether
the child had been admitted, where, at what age and with
which symptoms. These reports were examined individually in
relation to the admission register. When the mother reported
an “admission” not found in the register, reported symptoms
were usually diarrhea and vomiting (85% [78/92]; measles
vaccine, 29; no vaccine, 49). According to local practice, indi-
viduals with diarrhea are rehydrated and then sent home
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without being registered as having been admitted to the hospi-
tal. Mothers reported hospital admission of 14 children with
fever or presumptive malaria (measles vaccine, 2; no vaccine,
12), data for which could not be found in the register. Maternal
reports on admissions had no dates and could therefore not be
included in the analysis. Inconsistencies between maternal
reports and register could be due to the mother misinterpreting
observation at the outpatient clinic as an “admission” or due to
the mother reporting a wrong date of birth or bringing no or
the wrong vaccination card to the hospital. Furthermore, chil-
dren may have Portuguese names, ethnic names, or nicknames,
and if a name differs from the one in the demographic ﬁles it
may be difﬁcult to identify the child.
Follow-up
All children were called for the 9-month vaccination. However,
mothers often stay with relatives or take part in the harvest of
cashew nuts in the rural areas; some children will therefore not
be home when called. We kept calling to offer measles vaccine,
until children were 18 months old. As in the survival analysis
[13], we followed children from enrollment until they received
the 9-month measles vaccine or were censored at 18 months of
age. Because a long follow-up duration can dilute the effect of
early measles vaccine, our results are limited to follow-up data
up to 9 months of age (304 days).
Statistical Analyses
The statistical analyses were conducted in Stata 12. Follow-up
started at enrollment and ended at death, migration, receipt of
the 9-month vaccination, or at 18 months of age for children
who were not yet vaccinated, whichever came ﬁrst. Children
did not contribute follow-time during admission; follow-up
time resumed at discharge. We present follow-up time with ad-
mission hazard rate ratios (HRRs) and Wald 95% CIs estimated
from a Cox proportional hazards model with age as underlying
time. Use of time since inclusion as underlying time did not
yield a difference in the results. The proportional hazards
assumption was assessed graphically and was tested using
Schoenfeld residuals (P = .95). Age was inherently controlled
for in the model. Multiple admissions were allowed. Following
an admission, the risk of a second admission was assumed to
be the same as the risk of the ﬁrst admission. As in previous
analyses [13], we adjusted for district by stratiﬁcation. In case
there were 0 hospital admissions (admission HRR, 0), CIs were
obtained by a proﬁle likelihood method, inverting results of the
likelihood ratio test into a CI. CIs for interactions involving 0
admissions were calculated similarly. In case there were no ad-
missions in one group, groups were compared by a log-rank
test. To account for death, competing risk methods were used
to calculate cumulative incidence curves for group A versus
groups B and C combined.
Exclusions
As in previous analyses [13, 16], 231 children were excluded.
Eighty children reported measles virus infection before enroll-
ment; 131 were enrolled within 25 days of DTP3 vaccination,
owing to a programming error; 18 were enrolled twice; and 2
had the wrong age on record, being 1 year older than indicated
in the demographic ﬁle.
Ethics
The protocol was approved by the Danish Central Ethical Com-
mittee, the Gambia/MRC scientiﬁc and ethics committees, and
the Guinean Ministry of Health’s Research Coordination Com-
mittee. Study participants had access to free consultations at
the local health centers and to essential drugs free of charge.
The clinical trials registration number was NCT00168558.
RESULTS
Participant Flow
We enrolled children between August 2003 and April 2007.
The study proﬁle has been described previously ([13] Figure 1);
2129 were randomly assigned to receive EZ measles vaccine at
4.5 and 9 months of age, and 4288 were randomly assigned to
receive no vaccine at 4.5 months of age. There were no major
differences in demographic, socioeconomic, and health related
background factors for the early receipt group and the control
group ([13] Table 1). The median age at the 9-month measles
vaccine was 274 days (interquartile range, 271–278 days) in the
early receipt group and 273 days (271–276 days) in the control
group. Furthermore, there was no difference in hospital admis-
sions before enrollment (relative risk [RR], 1.03 [95% CI,
Figure 1. The cumulative incidence of hospital admissions, according
to randomization group. Early recipients received measles vaccine at 4.5
and 9 months of age, and controls received vaccine at 9 months of age.
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0.80–1.33]). Between enrollment and the 9-month measles
vaccine, 221 hospital admissions were detected.
Main Results
Children randomly assigned to the early vaccine group had sig-
niﬁcantly lower risk of admission (n = 57) than children in the
control group (n = 164; Table 1 and Figure 1). The effect on ad-
missions was strongest and separately signiﬁcant for girls, with
a reduction of 47% (95% CI, 14%–68%) but not for boys (14%
[95% CI, −26% to 42%]; Table 1). Results were similar when
the children were followed only to 9 months of age (Table 1).
The effect remained signiﬁcant for girls when measles-associat-
ed admissions were excluded (Table 1). There was no difference
in the median duration of admissions for early recipients (7
days [interquartile range, 4–9 days]) and controls (7 days [IQR,
5–9 days]). The hospital case-fatality rate was 7% (4/57) for
early recipients and 9% (14/164) for controls.
Only 8% (17/221) of admissions were related to measles
virus infection (Table 2). The 2 main categories were presump-
tive malaria (42%) and pneumonia/respiratory infections
(35%). Both presumptive malaria (62%) and respiratory infec-
tions (58%) were slightly more common in the rainy season
(Supplementary Table 1). Early receipt of measles vaccine had
similar protective effects in the 2 main disease groups (Table 2).
There was no sex-associated difference for admissions due to
presumptive malaria, whereas the beneﬁcial effect on admis-
sions for respiratory infections differed signiﬁcantly for girls
(admission HRR, 0.31 [95% CI, 0.12–0.79]) and boys (admis-
sion HRR, 1.24 [95% CI, 0.65–2.36]; P = .02, test of interaction;
Supplementary Table 2).
As hypothesized, the beneﬁcial effect was most pronounced
for children receiving measles vaccine in the dry season (De-
cember–May), with a reduction of 47% (95% CI, 14%–67%),
whereas there was little effect for children vaccinated in the
rainy season (June–November; 14% [95% CI, −28% to 42%];
Table 3).
Analysis by NVAS Status
NVAS neutralized the beneﬁcial effect of early measles vaccine
[13]; we therefore made separate analyses for children, by
NVAS status (Tables 1–3 and Supplementary Figure 1). The
beneﬁcial effects of measles vaccine on admission was strong
for children who had not received NVAS (admission HRR, 0.53
[95% CI, 0.34–0.84]), whereas there was little effect among
those who had received NVAS (admission HRR, 0.90 [95% CI,
0.60–1.35]; Table 1). Among children who had not received
NVAS, early receipt of measles vaccine had a signiﬁcant effect
on admissions for respiratory infections (admission HRR, 0.37
Table 1. Admission Rates Between 4.5 and 9 Months of Age and Admission Hazard Rate Ratio (HRR) for Early Recipients of Measles
Vaccine (Group A), Compared With Controls (Groups B and C), by Neonatal Vitamin A Supplementation (NVAS) and Sex
NVAS
Status,
Sex
Group A Groups B and C Admission HRRa (95% CI)
Admissions/100 Person-
Years (Admissions/Person-
Days), Children, No.
Enrolled
Children,
No.
Admissions/100 Person-Years
(Admissions/Person-Days),
Children, No.
Enrolled
Children,
No. All Admissionsb
Excluding
Measles
Admissions
Overall
Boys 9.5 (37/142 037) 1084 11.1 (86/282 311) 2151 0.86 (0.58–1.26) 0.96 (0.64–1.41)
Girls 5.3 (20/137 120) 1045 10.2 (78/278 905) 2137 0.53 (0.32–0.86) 0.59 (0.36–0.97)
All 7.5 (57/279 157) 2129 10.7 (164/561 216) 4288 0.70 (0.52–0.95) 0.78 (0.58–1.07)
No
NVAS
Boys 8.4 (17/73 485) 558 11.4 (46/147 115) 1130 0.73 (0.42–1.28) 0.80 (0.46–1.41)
Girls 3.0 (6/71 919) 549 10.3 (43/152 213) 1165 0.30 (0.13–0.70) 0.35 (0.15–0.82)
All 5.8 (23/145 404) 1107 10.9 (89/299 328) 2295 0.53 (0.34–0.84) 0.60 (0.38–0.95)
NVAS
Boys 10.6 (20/68 552) 526 10.8 (40/135 196) 1021 1.00 (0.58–1.71) 1.14 (0.66–1.98)
Girls 7.8 (14/65 201) 496 10.1 (35/126 692) 972 0.79 (0.42–1.46) 0.83 (0.45–1.56)
All 9.3 (34/133 753) 1022 10.5 (75/261 888) 1993 0.90 (0.60–1.35) 0.99 (0.66–1.50)
Data are from the national pediatric ward, Guinea-Bissau. Early recipients received measles vaccine at 4.5 and 9 months of age, and controls received vaccine at 9
months of age.
Abbreviation: CI, confidence interval.
a Calculated as A/[A + B].
b With follow-up to only 9 months of age, the admission HRR was 0.72 (95% CI, 0.53–0.97) for all children, 0.53 (95% CI, 0.32–0.88) for girls, and 0.87 (95% CI,
0.59–1.29) for boys; among children who did not receive NVAS, the HRR was 0.56 (95% CI, 0.35–0.88) for all children, 0.32 (95% CI, 0.13–0.74) for girls, and 0.76
(95% CI, 0.43–1.33) for boys; for children who received NVAS, the HRR was 0.89 (95% CI, 0.59–1.35) for all children, 0.77 (95% CI, 0.40–1.46) for girls, and 1.00
(95% CI, 0.58–1.72) for boys.
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[95% CI, 0.16–0.89]) but not for presumptive malaria (admis-
sion HRR, 0.62 [95% CI, 0.31–1.26]; Table 2), and the beneﬁ-
cial effect on hospital admissions for respiratory infections
differed signiﬁcantly between girls (admission HRR, 0 [95% CI,
0–0.23]) and boys (admission HRR, 0.84 [95% CI, 0.32–2.20];
Supplementary Table 2), with a female-to-male admission
HRR of 0 (95% CI, 0–0.33).
DISCUSSION
Early receipt of measles vaccine was associated with a lower risk
of hospital admission; this effect was separately signiﬁcant for
girls. The reduction in overall and non–measles-related causes
of admission were found mainly among children who had not
received NVAS; the beneﬁcial effect of early receipt of measles
vaccine was particularly marked for respiratory infections, es-
pecially in girls.
This is the ﬁrst randomized controlled trial of the nonspecif-
ic effects of measles vaccine in which hospital admissions have
been monitored to detect the likely causes of the differential
effect of measles vaccine on child survival. It was not a placebo-
controlled trial because we did not want mothers to believe er-
roneously that their child had already received measles vaccine
[13]. The physicians at the pediatric ward could have looked at
the vaccination card to see whether the child had received an
additional measles vaccine. However, they were unlikely to do
so, and if it had affected the likelihood of being admitted it
would presumably have affected all disease categories equally.
There is no ofﬁcial register of children being admitted or, for
that matter, of children leaving the pediatric ward. The only
register is the one that the BHP maintains and that BHP staff
have to check daily about what happened to all currently admit-
ted children, to detect who died, ﬂed, or was discharged. As dis-
cussed above, a few admissions may not have been registered.
Addition of the 14 cases of fever and presumptive malaria re-
ported by others but not found in the register would strengthen
the protective effect of measles vaccine against admissions.
Resources are limited at the ward, and most diagnoses are
clinical rather than laboratory conﬁrmed. The seasonal diffe-
rence in malaria admission was not very marked (Supplemen-
tary Table 1), but malaria is transmitted all year round in
Bissau, although it is more frequent in the late rainy season and
early dry season [19]. Hence, diagnostic categories should be
interpreted cautiously. The fever interpreted as malaria may
well be sepsis, and malaria may well be misdiagnosed as respi-
ratory infections in the rainy season, as found in the Gambia
[20]. Still the beneﬁcial effect of measles vaccine was strongest
in the dry season, and it seems plausible that the majority of re-
spiratory infections were indeed “respiratory” and that measles
vaccine has a particularly strong effect on respiratory infections.
Around 6% in the control group against only 1% in the early
receipt group received measles vaccine elsewhere before theyTa
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turned up for the 9-month vaccination session (Figure 1) [13].
This information has not been taken into consideration in the
analysis of admission rates because the information was only
available retrospectively for children who survived. Hence,
control children have been assigned too much follow-up time
in the no-vaccine group (DTP3 vaccinated). The admission
HRRs are therefore conservative, and the true effect of early
receipt of measles vaccine may have been slightly stronger.
The protective effect of measles vaccine against admission
was similar to what we have previously reported for mortality
[13]. Early receipt of measles vaccine reduced both admissions
and mortality among children who had not received NVAS.
These effects were stronger and signiﬁcant for girls but not
for boys.
In the same pediatric department, we have previously con-
ducted observational studies, comparing hospital case-fatality
rates of different infections for measles vaccine recipients and
nonrecipients, with the latter group usually having DTP as
their most recent vaccination [21]. The adjusted case-fatality
rate in the group aged 6–17 months was 2-fold lower for
measles vaccine recipients (mortality ratio [MR], 0.51 [95% CI,
0.27–0.98]), and this effect was particularly marked for pneu-
monia (MR, 0.28 [95% CI, 0.07–0.91]). A similar nonsigniﬁ-
cant trend was observed for fever or presumptive malaria
(RR, 0.30 [95% CI, 0.13–1.18]), whereas nothing was found for
diarrhea (RR, 1.38 [95% CI, 0.29–9.36]) and other conditions
(RR, 0.75 [95% CI, 0.27–2.89]). This differential effect on rela-
tive severity of different diseases is similar to that in the present
study.
There is yet no explanation of the beneﬁcial nonspeciﬁc
effects of measles vaccine, but some mechanisms are clearly
possible. Animal studies of heterologous immunity have shown
that priming with one pathogen may either enhance or reduce
susceptibility to subsequent infection with unrelated pathogens
[22, 23]. One explanation of why respiratory infections are
more affected may be that beneﬁcial heterologous cross-reac-
tions are more common between measles virus and other
related paramyxoviruses, such as respiratory syncytial virus,
parainﬂuenza virus, and inﬂuenza virus. The effect was signiﬁ-
cant and more marked on admissions in the dry season, when
admissions for respiratory infections are common [24] and
when the diagnosis is less likely to be confounded by the con-
comitant presence of malaria [20]. Training of the innate
immune system with BCG has been shown to induce nonspe-
ciﬁc protection through epigenetic reprogramming of mono-
cytes [25], and a similar mechanism may also apply to measles
vaccine. Furthermore, children who had maternal antibodies at
time of measles vaccination had better survival than children
who received measles vaccine in the presence of no detectable
antibodies [26].
In animal studies of live and inactivated vaccines of the same
antigen, the live vaccine has generally been associated with a
better capacity to handle a subsequent challenge [27–31].
Hence, the reduction in admissions for girls who received
measles vaccine, compared with girls who received DTP3 as
their most recent vaccine, could be related to differences in
immune priming with a live or inactivated vaccine. It is not
known why these effects would differ for girls and boys.
Table 3. Admission Rates Between 4.5 and 9 Months of Age and Admission Hazard Rate Ratio (HRR) for Recipients of Early Measles
Vaccine (Group A), Compared With Controls (Groups B and C), by Season of Enrollment
NVAS
Status,
Season
Group A Groups B and C Admission HRR (95% CI)
Admissions/100 Person-
Years (Admissions/Person-
Days), Children, No.
Enrolled
Children,
No.
Admissions/100 Person-Years
(Admissions/Person-Days),
Children, No.
Enrolled
Children,
No.
All
Admissions
Excluding
Measles
Admissions
Overall
Dry 5.4 (21/142 294) 1063 10.1 (80/287 701) 2149 0.53 (0.33–0.86) 0.62 (0.38–1.01)
Rainy 9.6 (36/136 863) 1066 11.2 (84/273 515) 2139 0.86 (0.58–1.28) 0.93 (0.63–1.38)
All 7.5 (57/279 157) 2129 10.7 (164/561 216) 4288 0.70 (0.52–0.95) 0.78 (0.58–1.07)
No NVAS
Dry 5.2 (11/76 721) 570 11.1 (47/154 524) 1165 0.47 (0.24–0.91) 0.54 (0.28–1.05)
Rainy 6.4 (12/68 683) 537 10.6 (42/144 804) 1130 0.61 (0.32–1.15) 0.67 (0.35–1.28)
All 5.8 (23/145 404) 1107 10.9 (89/299 328) 2295 0.53 (0.34–0.84) 0.60 (0.38–0.95)
NVAS
Dry 5.6 (10/65 573) 493 9.0 (33/133 177) 984 0.62 (0.31–1.26) 0.73 (0.36–1.51)
Rainy 12.8 (24/68 180) 529 11.9 (42/128 711) 1009 1.09 (0.66–1.81) 1.15 (0.69–1.91)
All 9.3 (34/133 753) 1022 10.5 (75/261 888) 1993 0.90 (0.60–1.35) 0.99 (0.66–1.50)
Data are from the national pediatric ward, Guinea-Bissau. Early recipients received measles vaccine at 4.5 and 9 months of age, and controls received vaccine at 9
months of age.
Abbreviations: CI, confidence interval; NVAS, neonatal vitamin A supplementation.
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However, the female and male immune systems are undoubted-
ly different. It is not common to report effects of interventions
separately for girls and boys; however, we have found in many
observational studies and randomized trials that the effects of
measles vaccine, DTP, BCG, and vitamin A supplementation
differ for girls and boys [32–34]. NVAS appears to reprogram
the immune system in ways that interact with other interven-
tions throughout infancy and that often differ for girls and boys
[34–37]. Likewise, it is uncommon to report effects of vaccines
separately by season. However, there are major differences in
the immune system and exposure patterns in the dry and the
rainy season [38, 39]. On the basis of previous experience, we
had hypothesized that the beneﬁcial effect of measles vaccine
would be strongest in the dry season. In the present trial, chil-
dren enrolled at 4.5 months of age in the dry season had a
higher level of maternal antibodies than children enrolled in
the rainy season [40]. Hence, the beneﬁcial immune stimula-
tion related to the presence of maternal antibodies may be
better in the dry season [26].
Essentially all vaccine research and policy decisions are
based on the assumption that vaccines protect against a speciﬁc
pathogen and nothing else, apart from any adverse events
linked to the initial challenge. The randomized trial of early
measles vaccine has shown that measles vaccine has additional
beneﬁcial effects on child survival [13], and the present study
suggests that early receipt of measles vaccine reduces hospital
admissions for non–measles-related infections. Taking these
effects into consideration could have major consequences for
child survival and healthcare costs. Pursuing these observa-
tions, we found in a Danish nationwide register-based study of
>500 000 children that measles, mumps, and rubella vaccine is
associated with a reduction of 14% (95% CI, 12%–16%) in the
risk of infectious diseases–associated hospital admissions [41];
this protective effect was signiﬁcantly better for lower respirato-
ry tract infections than for other kind of infections [42].
The current measles vaccine policy is based on the observa-
tion that seroconversion is better when maternal antibodies
have waned, and it is therefore recommended to delay measles
vaccine to 12 months of age once measles virus infection is
under control. This recommendation is based on no evidence
about the effect on overall health and survival. It might cost
lives and increase healthcare costs if children between 9 and 12
months of age were no longer to have the beneﬁcial nonspeciﬁc
effects of measles vaccine. With current evidence it would be
better to lower the age of the ﬁrst measles vaccine and to follow
receipt at this age with an additional measles vaccination at 9 or
18 months of age [13, 43]. NVAS clearly limited the beneﬁcial
effect of early receipt of measles vaccine. We have found in 3
trials in Guinea-Bissau (unpublished data) [34–36], that NVAS
was associated with signiﬁcantly higher female infant mortality.
Although NVAS may have some beneﬁt for boys [36], it is to be
hoped that NVAS does not become general policy for all children.
The Strategic Advisory Group of Experts of the World
Health Organization’s immunization program recently initiated
a review of the nonspeciﬁc effects of BCG, measles vaccine, and
DTP [44]. This will hopefully stimulate research into the real-
life effects of measles vaccine and other vaccines to understand
the full extent of these effects. Childhood mortality has been
declining in recent years, making it increasingly difﬁcult to
conduct studies with mortality as an outcome. It is therefore
important that the present study suggests that effects are
similar for mortality [13] and hospital admissions. For both
outcomes, early receipt of measles vaccine had beneﬁcial non-
speciﬁc effects that were stronger for girls than boys, tended to
be more marked in the dry season, and were neutralized by
NVAS.
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